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Abstract
The auxiliary regulatory protein Vpr of HIV-1 is packaged in the virion through interaction with the
Gag C-terminal p6 domain. Virion packaging of Vpr is critical for Vpr to exert functions in the HIV-
1 life cycle. Previous studies suggest that Vpr interacts with a (Lxx)4 domain in p6 for virion
packaging. In the present study, mutational analysis of HIV-1 Gag p6 domain was performed in the
context of the HIV-1 genome to examine the effect on virion packaging of Vpr. Surprisingly, Ala
substitutions for Leu44 and Phe45 in the (Lxx)4 domain or deletion of the whole (Lxx)4 domain
(amino acid #35–52 of the Gag p6 domain) did not affect Vpr virion packaging. Vpr virion packaging
was normal when amino acid #1–23 of the Gag p6 domain was preserved. Most importantly, Ala
substitutions for Phe15, Arg16 and Phe17 in the context of amino acid #1–23 of the Gag p6 domain
abolished Vpr virion packaging. Single Ala substitutions for Phe15 and Phe17 also abolished Vpr virion
packaging, whereas Ala substitution for Arg16 had no effect. Our studies have revealed a novel signal
sequence for Vpr packaging into the HIV-1 virion. The 15FRFG domain in p6 resembles the FxFG
repeat sequences commonly found in proteins of the nuclear pore complex. These results have
provided novel insights into the process of virion packaging of Vpr and suggest for the first time
that Vpr may recognize the FxFG domain for both virion packaging and association with nuclear
pores.
Findings
Vpr is a 15 kDa auxiliary regulatory protein of HIV-1 pro-
duced in the late phase of the viral life cycle and packaged
in the virion [1-3]. Thus, Vpr has the capacity to function
both in the early phase and the late phase of the viral life
cycle. A number of biological activities have been assigned
to Vpr, including nuclear localization [4-6], transcrip-
tional effects [7,8], cell cycle arrest at the G2/M check
point [9-13], and pro- and anti-apoptotic activities [14-
18]. In most cases the direct cellular target for Vpr remains
to be identified. It is possible that Vpr has multiple unre-
lated functions to facilitate HIV-1 interaction with the
host cells. Alternatively, some of the biological activities
of Vpr may be explained by a common mechanism.
Transiently expressed Vpr localizes in the nucleus, and
specific nuclear localization signals have been identified
in Vpr [6]. Vpr nuclear transport has been correlated with
interaction with importin a [19]. However, the nuclear
localization of Vpr appears to be more complicated since
Vpr is also found to interact with residents of the nuclear
pore complex [20]. Notably, Vpr is found to interact with
the FG repeat domain of rat Poml21, which is a nuclear
pore protein [20]. However, in similar assays Vpr fails to
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interact with the FG repeat domain of other nuclear pore
proteins [20]. Thus, the exact specificity of this interaction
remains uncharacterized.
Virion packaging of Vpr is through interaction with the
Gag C-terminal p6 domain [1]. With vaccinia expression
of HIV-1 Gag and Vpr, a (Lxx)4 domain (amino acid #35–
46) in HIV-1 p6 was determined to be essential for virion
packaging of Vpr [21]. Fusion of MLV Gag with the HIV-1
p6 domain allows the fusion protein to package Vpr [22].
Under this condition, single point mutations of L45A or
F46A within the (Lxx)4 domain abolish Vpr virion pack-
aging [22]. The direct interaction of HIV-1 p6 with Vpr
appears to be rather weak, detectible only by using a sen-
sitive in vitro assay [23]. The dissociation constant for the
p6-Vpr complex is between 18–75 µM [23]. It is hypothe-
sized that this weak interaction may be enhanced during
the process of virion packaging when Gag forms oligom-
ers [23]. Secondary interactions between Vpr and other
regions of Gag may also aid virion packaging of Vpr [24].
Interestingly, the HIV-1 p6 also has well-characterized
domains for binding cellular sorting factors Tsg101 and
AIP1 [25,26]. Whether these interactions influence Vpr
virion packaging remains unclear.
In this study, sequences in HIV-1 Gag p6 domain required
for Vpr virion packaging was dissected in the context of
the HIV-1 genome. Surprisingly, the previously identified
(Lxx)4 domain in p6 is shown non-essential for Vpr virion
packaging. Instead, a 15FRFG domain in HIV-1 Gag p6, 4
amino acid residues downstream of the Tsg101-binding
domain, is found critical for Vpr virion packaging. Since
FxFG domains also occurs in nuclear pore proteins, the
current finding also suggests for the first time that Vpr may
recognize the same FxFG domain for both virion packag-
ing and association with nuclear pores. Thus, the FxFG
domain appears to be a favorite signal for in vivo recogni-
tion by Vpr. We discuss the impact of this finding in the
context of the HIV-1 life cycle.
To examine the biochemical process of Vpr virion packag-
ing, we introduced various Gag p6 mutations into an HIV-
1 genome containing partial deletion of the Pol gene and
HA-tagged ubiquitin in place of the Nef gene. This modi-
fied HIV-1 genome was used to facilitate construction of
p6 mutants and to examine ubiquitination of HIV-1 pro-
teins. All HIV-1 genomic constructs were based on the
p89.6 plasmid [27] and their sequences were confirmed
by automatic sequence analysis. p89.6/Po1-/R+  and
p89.6/Pol-/R- constructs were described before [28]. A
BamHI site was inserted at the beginning of the Nef ORF
in a subclone of p89.6 carrying the 3' half of the HIV-1
genome, p89.6/3'[27], to generate p89.6/3'-BamHI. This
modification also resulted in deletion of the 5' region of
Nef ORF up to the KpnI site. Subsequently, the HA-Ub
coding sequence was PCR-amplified from the pCMV-HA-
Ub plasmid [29] with primer 1 AGTTACGGATCCAT-
GGCATAGCTACCCTTATGACGTC and primer 2
CATTCAGGATCCTACCCACCTCTGAGACGGAGGAC-
CAG, digested with BamHI and inserted into the p89.6/3'-
BamHI plasmid to generate p89.6/3'-HA-Ub. The EcoRI/
PstI-blunt fragment of p89.6/3'-HA-Ub was ligated to the
EcoRI/SmaI sites of p89.6/Pol-/R+ and p89.6/Pol-/R- to
generate p89.6/HA-Ub/R+  and p89.6/HA-Ub/R-con-
structs, respectively (labeled as HA-Ub/R+ and HA-Ub/R-
in Fig. 1).
The p89.6/Pr-/R+ and p89.6/Pr-(LF)a/R+ constructs were
prepared by inserting a PstI/StuI digested PCR DNA frag-
ment into the PstI/BalI sites of p89.6/HA-Ub/R+. For
p89.6/Pr-/R+, PCR was performed with the p89.6/5' clone
as the template [27], and primer 3 GGTACATCAG-
GCCATCTCACC and primer 4 CTGACCAGGCCTCCCG-
GGTTATTTTATTGTGACGAGGGGTCGTTGC. For p89.6/
Pr-(LF)a/R+, PCR was performed with the same template
and primer 3 and primer 5
CTGACCAGGCCTCCCGGGTTATTTTATTGTGACGAG-
GGGTCGTTGCCTGCGGC TGATCTGAGGGAAGC. For
constructs p89.6/Pr (Lxx)-/R+, p89.6/Pr-(1–23)/R+  and
p89.6/Pr (FRF)a/R+, the PCR DNA was digested with PstI/
SmaI and ligated into the PstI/SmaI sites of p89.6/Pr-
(LF)a/R+. For p89.6/Pr- (Lxx)-/R+, PCR was performed with
the p89.6/5' template and primer 3 and primer 6
GTACTACCCGGGAGGCCTTTATTCCTTGTCTATCG-
GCTCCTGC. For p89.6/Pr-(l-23)/R+, PCR was performed
with primer 3 and primer 7 GTACTACCCGGGAGGCCTT-
TATTGAGTTGTTGTCTCCTCCCCAAACC. For p89.6/Pr-
(FRF)a/R+, PCR was performed with primer 3 and primer
8 GTACTACCCGGGAGGCCTTTATTGAGTTGTTGTCTC-
CTCCCCGGCCGCGGCGC TCTCTGCTGG. The construct
p89.6/Pr-F15A/R+, p89.6/Pr-R15A/R+, and p89.6/Pr-F17A/
R+ were prepared in the same way as p89.6/Pr-(1–23)/R+,
except that the PCR was performed with primer 3 and a
new primer instead of primer 7: primer 9 (for p89.6/Pr-
F15A/R+) ACTCGACCCGGGAGGCCTTTATTGAGTTGTT-
GTCTCCTCCCCAAACCTGGCGC TCTCTGCTGG, primer
10 (for p89.6/Pr-  R16A/R+)
ACTCGACCCGGGAGGCCTTTATTGAGTTGTTGTCTC-
CTCCCCAAACGCGAAGC TCTCTGC, and primer 11 (for
p89.6/Pr-  F17A/R+) ACTCGACCCGGGAGGCCTTTATT-
GAGTTGTTGTCTCCTCCCCGGCCCTGAAGC TCTC. The
construct p89.6/Pr-  (l-23)/R+/∆ Ub was prepared by
removing the BamHI-BamHI fragment, encoding the HA-
tagged Ub gene, from the p89.6/Pr-(1–23)/R+ construct.
Cell culture and transfection were performed under con-
ditions described previously [18]. To obtain HIV-1 viri-
ons, three days after transfection, culture supernatant was
clarified by a low speed centrifugation followed by filtra-
tion through a 0.45 nm filter. The clarified cultureRetrovirology 2004, 1:26 http://www.retrovirology.com/content/1/1/26
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HIV-1 genomic constructs and requirements for Vpr virion packaging Figure 1
HIV-1 genomic constructs and requirements for Vpr virion packaging. A) All viral constructs were based on the 
p89.6/HA-Ub/R+. Pr-/R+: genomic construct carrying the wild type p6 and a premature stop codon for the protease ORF 
immediately after the p6 stop codon. All other clones were derived from the Pr-/R+ construct. Bold-typed regions represent 
binding sites for Tsg101, Vpr (this study), and AIP1. B) Effects of p6 mutations on virion packaging of Vpr. Experimental condi-
tions are described in "Findings". Left panels: Gag and Vpr Western blots with virion samples. Right panels: top two panels are 
Western blots of virion samples, whereas the bottom panel is Western blot of Vpr immunoprecipitated from cell lysates. C) 
Comparision of the 15FxFG domain in HIV-1 Gag p6 with the FxFG domains in human Pom121. HIV-1 p6 sequence is derived 
from isolate 89.6 [27], and the human Poml21 sequence is derived from GenBank accession number BC008794. Numbers indi-
cate the amino acid positions in the proteins.Retrovirology 2004, 1:26 http://www.retrovirology.com/content/1/1/26
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supernatant was subjected to centrifugation through a
20% sucrose cushion in the SW50.1 rotor at 33,000 rpm
for 1 hour. Virions from transfected 293 cells were exam-
ined for the presence of Gag and Vpr by Western blot anal-
ysis. As shown, Gag p55, p24, p17 as well as Vpr were all
detected in the virions with the R+ genome (Fig. 1B, lane
1). With the HIV-1 genome containing a premature stop
codon in Vpr (R- genome), no Vpr was detected in the vir-
ion (lane 2). We subsequently prepared a protease-trun-
cated construct based on the R+ genome, named Pr-/R+,
and observed normal Vpr virion packaging (Fig. 1B, lane
3). As expected, Gag p55 was not processed with the Pr-/
R+ construct due to the loss of protease. Surprisingly, nor-
mal Vpr virion packaging was still observed with the Pr-
(LF)a/R+ construct (lane 4), which contains L44A/F45A
double mutations in the Gag p6 domain (Fig. 1A) that are
reported to abolish Vpr packaging in the context of the
MLV Gag/HIV-1 p6 fusion construct [22]. The whole
(Lxx)4 domain was then deleted from p6 to generate the
Pr-(Lxx)-/R+ construct, and again normal Vpr packaging
was detected (Fig. 1B, lane 5).
The Pr-(Lxx)-/R+  construct still maintains a 15FRFG
domain in p6 which resembles the FxFG domain fre-
quently observed in resident proteins of the nuclear pore
[30]. To examine the potential involvement of this
domain in Vpr packaging, another p6 deletion construct
was prepared, with only aa #1–23 of p6 preserved (Fig.
1A). As shown, normal Vpr virion packaging was also
observed for this construct, Pr-(1–23)/R+ (Fig. 1B, lane 6).
Subsequently, 15FRF residues were all substituted by Ala
residues to generate the Pr-(FRF)a/R+ construct (Fig. 1A).
Importantly, this mutant failed to package Vpr into the
virion (Fig. 1B, lane 7).
To examine the roles of individual amino acid residues in
the  15FRFG domain during Vpr packaging, Phe15, Arg16
and Phe17 were individually substituted by Ala (Fig. 1A).
As shown, while single F15A and F17A mutations abol-
ished Vpr packaging (Fig. 1B, lanes 8 and 10), R16A muta-
tion had no effect (lane 9). Since all of the HIV-1
constructs expressed HA-tagged ubiquitin (HA-Ub), the
HA-Ub coding sequence was removed from the Pr-(1–
23)/R+ construct. As shown, removal of HA-Ub had no
effect on Vpr virion packaging (Fig. 1B, lane 11). Analysis
of cell lysates showed that all HIV-1 genomic constructs
expressed the same amount of Vpr in the cell (Fig. 1B,
lanes 5–11, bottom panel). These results strongly suggest
that the 15FRFG domain is critical for Vpr virion
packaging.
In this report we provide evidence that HIV-1 Vpr is pack-
aged into the virion through the previously unrecognized
15FRFG domain in the Gag p6 domain. The Vpr packaging
function of the 15FRFG domain is preserved when amino
acid #1–23 of p6 is retained. This function is abolished
when 15FRF are substituted by Ala residues. Our conclu-
sion is further supported by the finding that Ala substitu-
tions for Phe15 and Phe17abolish Vpr packaging whereas
Ala substitution for Arg16 has no effect. Previous studies
have shown that a (Lxx)4 repeat domain in Gag p6 is
essential for Vpr virion packaging [21,22]. The exact rea-
son for the discrepancy is unclear. However, the previous
studies were based on vaccinia expression of Gag and Vpr
[21] or on the MLV Gag/HIV-1 p6 fusion constructs [22].
It is possible that different experimental conditions affect
the virion packaging of Vpr. Alternatively, different HIV-1
strains may prefer the 15FRFG domain or the (Lxx)4
domain for Vpr packaging. It is noticeable that although
the 15FRFG domain is highly conserved among different
HIV-1 strains, it is replaced with 15FRSG in the HIV-1
Hxb2 strain (GenBank accession number K03455) and
15VRFG in the Yu-2 strain (GenBank accession number
AF287352). Future studies may reveal if an engineered
FRFG domain in these HIV-1 strains can allow Vpr pack-
aging in the absence of the (Lxx)4 domain.
Significantly, the 15FRFG domain of p6 resembles the
FxFG domains of certain nucleoporins with respect to
both the FxFG core and the following hydrophilic residues
rich in Ser/Thr residues (Fig. 1C). Thus, Vpr appears to rec-
ognize the same sequence for both virion packaging and
association with the nuclear envelope for transport into
the nucleus. We hypothesize that the FxFG domain is one
of the most important signals for Vpr recognition in vivo.
It may govern Vpr function during both the late phase and
the early phase of the HIV-1 life cycle.
Vpr interaction with nucleoporins has been reported
before [20]. In particular, Vpr is found to interact with the
FG repeat domain of Pom121 and more weakly with that
of Nsp1p [20]. It has been suggested that the FG residues
in these FG repeats constitute the hydrophobic core that is
critical for recognition by other proteins [30]. However,
the property of this hydrophobic core and the specificity
of protein-protein recognition are critically dependent on
the neighboring residues preceding the FG residues, so
that the FxFG, GLFG, and other types of FG repeats may be
involved in different protein-protein interactions [30].
Comparison of the Gag FxFG domain with the seven of
the FxFG repeats of the human Pom121 reveals that these
FxFG domains are followed by a sequence rich in Ser/Thr
residues (Fig. 1C) which may be critical for the function of
the FxFG domain. The roles of these Thr residues in Vpr
virion packaging remain to be dissected.
It is likely that Vpr recognizes the FxFG domain and not
other types of FG repeats. Single Ala substitution for Phe15
in the 15FRFG domain of p6 abolishes Vpr virion packag-
ing (Fig. 1). The nucleoporin Nup159p does not interactRetrovirology 2004, 1:26 http://www.retrovirology.com/content/1/1/26
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with Vpr [20], and its FG repeat domain contains eight
PxFG repeats and no FxFG repeat. In contrast, the FG
repeat domain of the Vpr-interacting nucleoporin
Pom121 contains seven copies of the FxFG repeats and six
copies of the PxFG repeat. Another nucleoporin that inter-
acts with Vpr weakly, Nsp1p, has a large number of FxFG
repeats. However, it is expected that nucleoporins func-
tion in the context of a large protein complex and their
conformations and interaction with Vpr may be influ-
enced by the presence of other interaction partners.
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